Purchase this article with an account.
Y. Sakurada, T. Kubota, T. Toyoaki, M. Imasawa, F. Mabuchi, A. Sekine, N. Tanabe, H. Iijima; Association of LOC387715 A69S Genotype With Visual Prognosis After Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3439.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate whether there is an association of LOC387715 A69S genotype with visual outcomes of photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV)
This study comprised of 63eyes of 63 PCV patients. All patients were treated with PDT and were followed up more than 12 months. PDT was performed until polypoidal lesions were disappeared on indocyanine green angiography or exudative changes on fluorescein angiography were not active. To genotype A69S site at the LOC387715 gene, denaturing high-performance chromatography was performed.
Though there was not a statistically significant difference in visual acuity among three genotype at baseline (P=.56, ANOVA), there was a statistically significant difference among three genotype (P=.043, ANOVA) at 12 month . At the final visit, mean visual acuity improved from 0.72 to 0.60 (log MAR unit) for the TG genotype and from 0.68 to 0.28 for the GG genotype, while that of TT genotype fell from 0.62 to 0.89 at final visit (P=0.0015, ANOVA). The recurrence of the lesion was observed in 10(41.6%) eyes in the TT genotype, 5(18.2%) eyes in the TG genotype, 1(8.9%) eye in the GG genotype during the follow up, respectively (P=0.023,Chi-square test).
With treatment of PDT, T allele at the LOC387715 was asscociated with visual prognosis and with incidence of the lesion recurrence.LOC387715 A69S genotype could have clinical importance in predicting visual prognosis after PDT for PCV. In this study, the potential pharmacogenetic association was observed to suggest interaction between LOC387715 A69S genotype and visual prognosis after PDT for PCV.
This PDF is available to Subscribers Only